266 related articles for article (PubMed ID: 26795275)
1. Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma.
Kong BY; Micklethwaite KP; Swaminathan S; Kefford RF; Carlino MS
Melanoma Res; 2016 Apr; 26(2):202-4. PubMed ID: 26795275
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy-associated autoimmune hemolytic anemia.
Khan U; Ali F; Khurram MS; Zaka A; Hadid T
J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
[TBL] [Abstract][Full Text] [Related]
3. Severe Allograft Rejection and Autoimmune Hemolytic Anemia After Anti-PD1 Therapy in a Kidney Transplanted Patient.
Deltombe C; Garandeau C; Renaudin K; Hourmant M
Transplantation; 2017 Sep; 101(9):e291. PubMed ID: 29633980
[No Abstract] [Full Text] [Related]
4. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of serologic markers related to red blood cell autoantibodies production after red blood cell transfusion-severe autoimmune hemolytic anemia occurring after transfusion and alloimmunization: successful treatment with rituximab.
Sigler E; Shvidel L; Yahalom V; Berrebi A; Shtalrid M
Transfusion; 2009 Jul; 49(7):1370-4. PubMed ID: 19374728
[TBL] [Abstract][Full Text] [Related]
6. An Autoimmune Haemolytic Anaemia Secondary to Ipilimumab Treatment.
Ramos B; Gastal G; Rovere RK
Klin Onkol; 2017; 30(2):128-130. PubMed ID: 28397508
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report.
Tardy MP; Gastaud L; Boscagli A; Peyrade F; Gallamini A; Thyss A
Hematol Oncol; 2017 Dec; 35(4):875-877. PubMed ID: 27539158
[TBL] [Abstract][Full Text] [Related]
8. Recurrent checkpoint inhibitor-induced warm agglutinin autoimmune hemolytic anemia in a patient with metastatic melanoma.
Hwang SR; O'Dowd T; Markovic SN; Wolanskyj-Spinner AP
Am J Hematol; 2020 Jul; 95(7):E169-E171. PubMed ID: 32243616
[No Abstract] [Full Text] [Related]
9. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
10. A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab.
Olson DJ; Rajagopal P; Tjota MY; Venkataraman G; Luke JJ; Gajewski TF
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169870
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
12. Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.
Maurice C; Schneider R; Kiehl TR; Bavi P; Roehrl MH; Mason WP; Hogg D
Cancer Immunol Res; 2015 Dec; 3(12):1299-302. PubMed ID: 26419960
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review.
Gauci ML; Laly P; Vidal-Trecan T; Baroudjian B; Gottlieb J; Madjlessi-Ezra N; Da Meda L; Madelaine-Chambrin I; Bagot M; Basset-Seguin N; Pages C; Mourah S; Boudou P; Lebbé C; Gautier JF
Cancer Immunol Immunother; 2017 Nov; 66(11):1399-1410. PubMed ID: 28634815
[TBL] [Abstract][Full Text] [Related]
14. Immune hemolytic anemia with drug-induced antibodies to carboplatin and vincristine in a pediatric patient with an optic pathway glioma.
Betensky M; Witmer C; Fisher MJ; Nance S; Weiss MJ; Sesok-Pizzini DA
Transfusion; 2014 Nov; 54(11):2901-5. PubMed ID: 24860959
[TBL] [Abstract][Full Text] [Related]
15. Direct antiglobulin ("Coombs") test-negative autoimmune hemolytic anemia: a review.
Segel GB; Lichtman MA
Blood Cells Mol Dis; 2014 Apr; 52(4):152-60. PubMed ID: 24411920
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases.
Jacobsoone-Ulrich A; Jamme P; Alkeraye S; Dzwiniel V; Faure E; Templier C; Mortier L
Melanoma Res; 2016 Apr; 26(2):153-6. PubMed ID: 26636908
[TBL] [Abstract][Full Text] [Related]
17. Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease.
Maul LV; Weichenthal M; Kähler KC; Hauschild A
J Immunother; 2016 May; 39(4):188-90. PubMed ID: 27023060
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune hemolytic anemia in patients with relapsed Hodgkin's lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1.
Tao Y; Han J; Li Y
Invest New Drugs; 2022 Aug; 40(4):854-857. PubMed ID: 35503192
[TBL] [Abstract][Full Text] [Related]
19. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
[TBL] [Abstract][Full Text] [Related]
20. Positive direct antiglobulin tests and immune hemolytic anemia in patients receiving procainamide.
Kleinman S; Nelson R; Smith L; Goldfinger D
N Engl J Med; 1984 Sep; 311(13):809-12. PubMed ID: 6332273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
